SC
PTCT icon

SummitTX Capital’s PTC Therapeutics PTCT Stock Holding History

SummitTX Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19M Buy
+14,579
New +$1.05M 0.03% 425
2025
Q4 		– Sell
-102,734
Closed -$6.3M – 917
2025
Q3 		$6.3M Buy
102,734
+88,826
+639% +$4.63M 0.26% 89
2025
Q2 		$679K Sell
13,908
-6,841
-33% -$325K 0.03% 448
2025
Q1 		$1.06M Buy
+20,749
New +$1.04M 0.05% 398

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

SummitTX Capital's PTCT Position: Q2 2026 in Review

SummitTX Capital opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 14,579 shares worth $1.19M. The stake represents 0.03% of the portfolio and ranks #425 among its holdings. This is a return to the name: SummitTX Capital previously reported a position in PTCT as recently as Q3 2025.

SummitTX Capital first reported a position in PTCT in Q1 2025 and has held it in 4 quarters since. The position peaked at $6.3M in Q3 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • SummitTX Capital held 14,579 shares of PTC Therapeutics worth $1.19M as of Q2 2026.
  • PTC Therapeutics was a new SummitTX Capital position in Q2 2026.
  • PTC Therapeutics made up 0.03% of SummitTX Capital's portfolio in Q2 2026, its #425 holding.
  • SummitTX Capital first reported a position in PTC Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • SummitTX Capital's PTC Therapeutics position peaked at $6.3M in Q3 2025.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.